Interim safety summary of alemtuzumab vs. chlorambucil as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia (BCLL) This is an ASCO Meeting Abstract from the 2004 ...
TNKase is administered as a single intravenous bolus over 5 seconds. The Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase) for the treatment of acute ischemic stroke (AIS) in ...
Oral Capecitabine Compared With Intravenous Fluorouracil Plus Leucovorin in Patients With Metastatic Colorectal Cancer: Results of a Large Phase III Study Various pharmacologic strategies have been ...
Thrombolytic therapy with alteplase is widely used for symptomatic PVT, but evidence comparing it directly with tenecteplase ...
The usual but empirical initial dose in brain tumor patients is an intravenous bolus of 10 mg of dexamethasone, followed by a maintenance dose of 4 mg given by the intravenous (IV) route every 6 hours ...
Please provide your email address to receive an email when new articles are posted on . TNKase is the first stroke treatment approved by the FDA in almost 30 years, the manufacturer said. It is ...
People aged 16 or over at high risk of severe illness or death from sepsis in acute hospital settings have an intravenous fluid bolus within 1 hour of risk being identified, unless contraindicated.
oxaliplatin — 5mg/mL soln for IV infusion after dilution Day 1: 85mg/m² + leucovorin, followed by 5−FU. Day 2: Leucovorin followed by 5−FU. Give by IV infusion every 2wks for a total of 6mos (12 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback